ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V.

NASDAQ:PRQR

Overview | Financials
Company Name ProQR Therapeutics N.V.
Symbol PRQR
Currency USD
Price 2.68
Market Cap 276,586,720
Dividend Yield 0%
52-week-range 1.61 - 4.62
Industry Biotechnology
Sector Healthcare
CEO Mr. Daniel Anton de Boer
Website https://www.proqr.com

An error occurred while fetching data.

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial

Related Stocks

MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

INKT

0.528 USD

BeyondSpring Inc. logo

BeyondSpring Inc.

BYSI

1.661 USD

Sera Prognostics, Inc. logo

Sera Prognostics, Inc.

SERA

8.1 USD

Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc.

CRVS

5.29 USD

Syros Pharmaceuticals, Inc. logo

Syros Pharmaceuticals, Inc.

SYRS

0.216 USD

Freeline Therapeutics Holdings plc logo

Freeline Therapeutics Holdings plc

FRLN

6.49 USD

Catalyst Biosciences, Inc. logo

Catalyst Biosciences, Inc.

CBIO

0.511 USD

BioSig Technologies, Inc. logo

BioSig Technologies, Inc.

BSGM

1.43 USD

Financials

Numbers are in millions USD

Numbers are in millions USD